ClinicalTrials.gg
TerminatedNCT01459913CONCISEUpdated Jun 10, 2015Results posted

Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype

A Phase 3 interventional study of Telaprevir and Pegylated Interferon Alfa-2a in Hepatitis C, Chronic, sponsored by Vertex Pharmaceuticals Incorporated. Terminated at 83 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-06-10.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated early by the sponsor on 13 January 2014 due to a decision to modify the drug development plan.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
239
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing telaprevir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. telaprevir · Hepatitis C, Chronic.

Enrollment
3rd of 27
239 · median 54
Started
2011
with 3 others
Phase 3
12 of 27
none open now
Registered
12th of 27
by date
Lead sponsor
4 of 27
Vertex Pharmaceuticals Incorporated

Among the 27 studies testing telaprevir in Hepatitis C, Chronic, this one is the 3rd largest by enrollment, is one of 4 that started in 2011, is one of 12 in phase 3, and was the 12th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 27 studies testing telaprevir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About telaprevir

telaprevir: first FDA approval 2011 (INCIVEK), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 27 studies testing telaprevir in Hepatitis C, Chronic as a file.
02

Study summary

The purpose of this study is to evaluate if a 12-week total regimen of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV) (T12/PR12) is safe and effective in subjects who have the interleukin-28B (IL28B) CC genotype. The subjects enrolled in this study will have chronic hepatitis C virus (HCV) infection and will not have cirrhosis of the liver.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

Keywords

  • VX-950
  • INCIVEK
  • INCIVO
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects, 18 to 70 years of age, inclusive
  • Treatment-naive OR subjects (prior relapsers) may be included who did not achieve sustained viral response 24 weeks after last planned dose of study drug (SVR24) after at least 1 prior course of Peg-IFN/RBV therapy of standard duration and had a documented undetectable level at the planned end of treatment of at least 42-week duration
  • Subjects have IL28B CC genotype determined during screening
  • Subjects have genotype 1 chronic hepatitis C and laboratory evidence of HCV infection for at least 6 months, defined by (1) documented HCV serology test at least 6 months before the first screening visit demonstrating the presence of anti-HCV antibody, or (2) documented presence of HCV RNA by a sensitive and specific assay at least 6 months before the first screening visit, or (3) documented histologic evidence of chronic hepatitis C demonstrated by fibrosis on a standardized histologic grading system at least 6 months before the first screening visit. If only inflammation is present in the liver histologic report, then 6 months of laboratory evidence is required

Exclusion criteria

Exclusion Criteria:

  • Subjects have received previous treatment with telaprevir or any other protease inhibitor(s) for chronic
  • Subjects who did not achieve SVR24 after at least 1 prior course of Peg-IFN/RBV therapy of standard duration and never achieved undetectable HCV RNA while on treatment
  • Subjects have evidence of hepatic decompensation
  • Subjects have evidence of cirrhosis
  • Subjects have diagnosed or suspected hepatocellular carcinoma
  • Subjects have any other cause of significant liver disease in addition to hepatitis C, which may include but is not limited to with hepatic involvement, , drug or alcohol-related cirrhosis, hepatitis, hemochromatosis, Wilson's disease, nonalcoholic steatohepatitis, or primary biliary cirrhosis. Steatosis is allowed if clinically asymptomatic
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
239 participants (actual)

Study arms

  • Experimental
    Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)

    Telaprevir 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (\<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (\>=) 75 kg, for 12 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met rapid viral response (RVR, undetectable Hepatitis C Virus \[HCV\] Ribonucleic Acid \[RNA\] at Week 4) criteria, were randomized in this group, as planned, and did not receive any further treatment.

    Drug: Telaprevir · Drug: Pegylated Interferon Alfa-2a · Drug: Ribavirin

  • Experimental
    Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)

    Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 24 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met RVR criteria, were randomized in this group, as planned.

    Drug: Telaprevir · Drug: Pegylated Interferon Alfa-2a · Drug: Ribavirin

  • Experimental
    Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)

    Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 24 weeks. Only subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, and had extended rapid viral response (eRVR, undetectable HCV RNA at Weeks 4 and 12), were included in this group, as planned.

    Drug: Telaprevir · Drug: Pegylated Interferon Alfa-2a · Drug: Ribavirin

  • Experimental
    Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)

    Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 48 weeks. Only subjects with no RVR or no RVR assessment, and subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, who did not have eRVR or eRVR assessment, were included in this group, as planned.

    Drug: Telaprevir · Drug: Pegylated Interferon Alfa-2a · Drug: Ribavirin

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)

    SVR12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at 12 weeks after last planned dose of study drug. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

    Time frame: 12 weeks after last planned dose of study drug (up to Week 36)

Secondary outcomes

  1. Percentage of Subjects With Sustained Viral Response 4 Weeks After Last Planned Dose of Study Drug (SVR4)

    SVR4 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at 4 weeks after last planned dose of study treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

    Time frame: 4 weeks after last planned dose of study drug (up to Week 28)

  2. Percentage of Subjects With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)

    SVR24 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at 24 weeks after last planned dose of study treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

    Time frame: 24 weeks after last planned dose of study drug (up to Week 48)

  3. Percentage of Subjects With Sustained Viral Response at Week 72 (SVR72)

    SVR72 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Week 72. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

    Time frame: Week 72

  4. Percentage of Subjects With Viral Relapse

    Viral relapse was defined as having detectable HCV RNA during antiviral follow-up in subjects who had HCV RNA less than (\<) lower limit of quantification (LLOQ) at end of treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The LLOQ was 25 IU/mL and the lower limit of detection was 10 IU/mL. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

    Time frame: After last dose of study drug up to 4 weeks (up to Week 28), 12 weeks (up to Week 36), 24 weeks (up to Week 48) antiviral follow-up

  5. Percentage of Subjects With On-Treatment Virologic Failure

    On-treatment virologic failure was defined as subjects who met futility (as per investigator discretion) or who completed the assigned treatment duration and had detectable HCV RNA at planned end of treatment (up to 48 weeks). This outcome was planned to be assessed in all reporting groups and results were to be reported for total arm as well.

    Time frame: Baseline up to Week 48

  6. Number of Subjects With Rapid Viral Response (RVR)

    The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. RVR was defined as undetectable HCV RNA 4 weeks after the start of study treatment. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

    Time frame: Week 4

  7. Number of Subjects With Extended Rapid Viral Response (eRVR)

    The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. eRVR was defined as undetectable HCV RNA at both 4 weeks and 12 weeks after the start of study treatment. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

    Time frame: Week 4 and Week 12

  8. Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AE: any adverse change from the subject's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not. An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug. SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. "Study drug" includes all investigational agents administered during the course of the study.

    Time frame: Baseline up to Week 48

07

Results

Posted Feb 11, 2015
Limitations and caveats
The study was terminated early at the primary efficacy endpoint (SVR12), by the sponsor on 13 January 2014 due to a decision to modify the drug development plan.

Participant flow

Participant flow — Overall Study
MilestoneTelaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)
Started106521962
Completed6532629
Not completed41201333
Withdrew: Adverse event0003
Withdrew: Withdrawal by subject4005
Withdrew: Lost to follow-up7418
Withdrew: Death0001
Withdrew: Non- compliance0003
Withdrew: Physician decision0100
Withdrew: Study terminated by sponsor3015911
Withdrew: Other0031
Withdrew: Did not meet inclusion criteria0001

Outcome measures

PrimaryPercentage of Subjects With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)

SVR12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at 12 weeks after last planned dose of study drug. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

Time frame:
12 weeks after last planned dose of study drug (up to Week 36)
Reported as:
Number · percentage of participants
Percentage of Subjects With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)
percentage of participantsTelaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)
Percentage of Subjects With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)88.796.2
SecondaryPercentage of Subjects With Sustained Viral Response 4 Weeks After Last Planned Dose of Study Drug (SVR4)

SVR4 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at 4 weeks after last planned dose of study treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

Time frame:
4 weeks after last planned dose of study drug (up to Week 28)
Reported as:
Number · percentage of participants
Percentage of Subjects With Sustained Viral Response 4 Weeks After Last Planned Dose of Study Drug (SVR4)
percentage of participantsTelaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)
Percentage of Subjects With Sustained Viral Response 4 Weeks After Last Planned Dose of Study Drug (SVR4)89.698.1
SecondaryPercentage of Subjects With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)

SVR24 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at 24 weeks after last planned dose of study treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

Time frame:
24 weeks after last planned dose of study drug (up to Week 48)
Reported as:
Number · percentage of participants
Percentage of Subjects With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)
percentage of participantsTelaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)
Percentage of Subjects With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)85.892.3
SecondaryPercentage of Subjects With Sustained Viral Response at Week 72 (SVR72)

SVR72 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Week 72. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

Time frame:
Week 72
Reported as:
Number · percentage of participants
Percentage of Subjects With Sustained Viral Response at Week 72 (SVR72)
percentage of participantsTelaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)
Percentage of Subjects With Sustained Viral Response at Week 72 (SVR72)72.486.5
SecondaryPercentage of Subjects With Viral Relapse

Viral relapse was defined as having detectable HCV RNA during antiviral follow-up in subjects who had HCV RNA less than (\<) lower limit of quantification (LLOQ) at end of treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The LLOQ was 25 IU/mL and the lower limit of detection was 10 IU/mL. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

Time frame:
After last dose of study drug up to 4 weeks (up to Week 28), 12 weeks (up to Week 36), 24 weeks (up to Week 48) antiviral follow-up
Reported as:
Number · percentage of participants
Percentage of Subjects With Viral Relapse
percentage of participantsTelaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)
4 Weeks1.90.0
12 Weeks7.50.0
24 Weeks10.40.0
SecondaryPercentage of Subjects With On-Treatment Virologic Failure

On-treatment virologic failure was defined as subjects who met futility (as per investigator discretion) or who completed the assigned treatment duration and had detectable HCV RNA at planned end of treatment (up to 48 weeks). This outcome was planned to be assessed in all reporting groups and results were to be reported for total arm as well.

Time frame:
Baseline up to Week 48
Reported as:
Number · percentage of participants
Percentage of Subjects With On-Treatment Virologic Failure
percentage of participantsTelaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)Telaprevir+Peg-IFN-alfa-2a, RBV (Total)
Percentage of Subjects With On-Treatment Virologic Failure0003.30.8
SecondaryNumber of Subjects With Rapid Viral Response (RVR)

The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. RVR was defined as undetectable HCV RNA 4 weeks after the start of study treatment. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

Time frame:
Week 4
Reported as:
Number · participants
Number of Subjects With Rapid Viral Response (RVR)
participantsTelaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)
Number of Subjects With Rapid Viral Response (RVR)10652
SecondaryNumber of Subjects With Extended Rapid Viral Response (eRVR)

The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. eRVR was defined as undetectable HCV RNA at both 4 weeks and 12 weeks after the start of study treatment. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.

Time frame:
Week 4 and Week 12
Reported as:
Number · participants
Number of Subjects With Extended Rapid Viral Response (eRVR)
participantsTelaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)
Number of Subjects With Extended Rapid Viral Response (eRVR)10551
SecondaryNumber of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE: any adverse change from the subject's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not. An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug. SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. "Study drug" includes all investigational agents administered during the course of the study.

Time frame:
Baseline up to Week 48
Reported as:
Number · participants
Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsTelaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)
AEs104511961
SAEs54313

Adverse events

Collected over Baseline up to Week 48. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)—5/106 (4.7%)104/106 (98.1%)
Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)—4/52 (7.7%)51/52 (98.1%)
Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)—3/19 (15.8%)19/19 (100%)
Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)—13/62 (21%)61/62 (98.4%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventTelaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)
AnaemiaBlood and lymphatic system disorders2/1063/522/197/62
Abscess oralInfections and infestations0/1060/521/190/62
BacteraemiaInfections and infestations0/1060/521/190/62
PneumoniaInfections and infestations0/1060/520/193/62
PyrexiaGeneral disorders0/1061/520/190/62
Perirectal abscessInfections and infestations0/1061/520/190/62
AstheniaGeneral disorders0/1060/520/191/62
Chest painGeneral disorders0/1060/520/191/62
FatigueGeneral disorders0/1060/520/191/62
HypotensionVascular disorders0/1060/520/191/62
Most frequent other events
Showing 10 of 346
Most frequent other events
EventTelaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)
NauseaGastrointestinal disorders49/10619/5213/1933/62
FatigueGeneral disorders55/10625/5212/1926/62
AnaemiaBlood and lymphatic system disorders42/10622/5210/1920/62
RashSkin and subcutaneous tissue disorders31/10615/529/1913/62
Influenza like illnessGeneral disorders28/10610/528/199/62
PruritusSkin and subcutaneous tissue disorders44/10617/528/1924/62
DiarrhoeaGastrointestinal disorders19/1066/526/1911/62
VomitingGastrointestinal disorders17/1066/526/1911/62
Dry skinSkin and subcutaneous tissue disorders11/10611/526/194/62
DizzinessNervous system disorders17/1066/526/1914/62

Baseline characteristics

Full Analysis (FA) Set included all subjects who received at least 1 dose of study drug and fulfilled all relevant inclusion criteria. One subject from "Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)" was excluded from the FA Set due to having HCV Genotype 6.

Age, Continuous
Age, Continuous(years)Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)Total
Mean46.1 ± 12.8244.8 ± 12.8954.4 ± 8.7049.8 ± 10.5647.4 ± 12.26
Sex: Female, Male
Sex: Female, Male(Participants)Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)Total
Female3916112995
Male6736832143
08

Study locations

83 sites
  • Birmingham, Alabama 35209, United States
  • Birmingham, Alabama 35294, United States
  • Phoenix, Arizona 85054, United States
  • La Jolla, California 93037, United States
  • Los Angeles, California 90027, United States
  • California
    Los Angeles, California 90048, United States
  • Sacramento, California 95817, United States
  • San Diego, California 92103, United States
  • San Diego, California 92105, United States
  • San Diego, California 92154, United States
  • California
    San Francisco, California 94115, United States
  • Farmington, Connecticut 06030, United States
  • New Haven, Connecticut 06511, United States
  • Bradenton, Florida 34209, United States
  • Gainesville, Florida 32224, United States
  • Jacksonville, Florida 32224, United States
  • Jacksonville, Florida 32256, United States
  • Orlando, Florida 32803, United States
  • Atlanta, Georgia 30308, United States
  • Marietta, Georgia 30060, United States
  • Honolulu, Hawaii 96817, United States
  • Chicago, Illinois 60611, United States
  • Chicago, Illinois 60612, United States
  • Baltimore, Maryland 21202, United States
  • Baltimore, Maryland 21287, United States
  • Columbia, Maryland 21045, United States
  • Boston, Massachusetts 02215, United States
  • Brockton, Massachusetts 02302, United States
  • Burlington, Massachusetts 01805, United States
  • Worcester, Massachusetts 01605, United States
  • Novi, Michigan 48202, United States
  • Kansas City, Missouri 64131, United States
  • Lebanon, New Hampshire 03756, United States
  • Egg Harbor Township, New Jersey 08234, United States
  • Vineland, New Jersey 08360, United States
  • Flushing, New York 11355, United States
  • Manhasset, New York 10030, United States
  • New York, New York 10003, United States
  • New York, New York 10021, United States
  • New York, New York 10029, United States
  • Chapel Hill, North Carolina 27599, United States
  • Charlotte, North Carolina 28203, United States
  • Durham, North Carolina 27710, United States
  • Pennsylvania
    Hershey, Pennsylvania 17033, United States
  • Arlington, Texas 76012, United States
  • Houston, Texas 77030, United States
  • San Antonio, Texas 78215, United States
  • Virginia
    Fairfax, Virginia 22031, United States
  • Falls Church, Virginia 22042, United States
  • Norfolk, Virginia 23502, United States
  • Richmond, Virginia 23249, United States
  • Seattle, Washington 98101, United States
  • Madison, Wisconsin 53715, United States
  • Madison, Wisconsin 53792, United States
  • Milwaukee, Wisconsin 53226, United States
  • Linz, 4010, Austria
  • Vienna, 1090, Austria
  • Vienna, 1160, Austria
  • Calgary, Alberta T2N 4Z6, Canada
  • Edmonton, Alberta T5M 1J7, Canada
  • Edmonton, Alberta T6G 2X8, Canada
  • Vancouver, British Columbia V6T 1Z3, Canada
  • Winnipeg, Manitoba R3E 3P4, Canada
  • Toronto, Ontario M5G 2N2, Canada
  • Toronto, Ontario M5T 2S8, Canada
  • Berlin, 10969, Germany
  • Dusseldorf, 40237, Germany
  • Frankfurt, 60590, Germany
  • Hamburg, 20099, Germany
  • Hannover, 30625, Germany
  • Koeln, 50937, Germany
  • Leipzig, 4103, Germany
  • Munich, 81377, Germany
  • Haifa, 31096, Israel
  • Haifa, 34362, Israel
  • Israel
    Jerusalem, 91120, Israel
  • Nazareth, 16100, Israel
  • Petah Tikva, 49100, Israel
  • Tel Hashomer, 52621, Israel
  • Bialystok, 16-540, Poland
  • Czeladz, 41-250, Poland
  • Myslowice, 41-400, Poland
  • Wroclaw, 50-220, Poland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2011
First posted
Oct 26, 2011
Start
Nov 2011
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Results first posted
Feb 11, 2015
Last update
Jun 10, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01459913
Responsible party
Sponsor
First posted
Oct 26, 2011
Start date
Nov 2011
Primary completion
Jan 2014
Completion
Jan 2014
Results posted
Feb 11, 2015
Last update
Jun 10, 2015

Study contacts

Mark Friedman, M.D.
study director · Vertex Pharmaceuticals Incorporated

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telaprevir · Peginterferon alfa-2a · Ribavirin

Start the discussion